Navigation Links
Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
Date:4/30/2010

the treatment of patients with bipolar disorder discussed in this press release, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets, including the market for RG2417 or other forms of uridine, and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
2. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
3. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
6. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Capstone Reports Additional High Grade Copper-Gold Results From Minto East
9. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
10. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Inc. (NYSE: PFE ) announced today that based on discussions ... commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment ... and that it will be voluntarily withdrawing the new drug application (NDA) ... , , ...
... , June 21 Celator Pharmaceuticals today announced that ... The research agreement provides for the utilization of Celator,s proprietary technology ... , , , ... are pleased that work with this research program has led to ...
Cached Medicine Technology:Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 2Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 3
(Date:8/1/2015)... ... 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural ... by the National Retail Federation, the largest retail trade association in the world, for ... business owners to be named as such. According to the NRF’s website, Retail Champions ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional ... portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 ... state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional ...
(Date:8/1/2015)... ... 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam have announced ... Apple AppStore. , The app is designed to track various metrics of wellness, ... to view personal health and use this information for positive behavior modification. Lume Wellness ...
(Date:8/1/2015)... ... ... reTXT ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... including ones already sent. , While text messaging has more features than it did ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the ... the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, ... as tried-and-true products that have stood the test of time. These include lighting ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2
... 10, 2011 Researchers at UT Southwestern Medical Center have ... drug that fights cancers that are dependent on a particular ... compound,s effectiveness at fighting tumors in mice. If it is ... on the compound to combat pancreatic and non-small cell lung ...
... Revises "McDonald Criteria" for Diagnosing MS -- Use of ... MS Awareness Week An international panel has revised ... multiple sclerosis, incorporating new data that should speed the ... of MS, organized and supported by the National MS ...
... , WEDNESDAY, March 9 (HealthDay News) -- Drinking ... the risk for developing both Alzheimer,s and some forms ... noting that full-fledged alcohol abuse accounts for about 10 ... consumption of just one to two drinks a ...
... Despite dramatically improved survival rates for childhood acute lymphoblastic ... from the disease. Work led by St. Jude Children,s ... CREBBP that may help the cancer resist steroid treatment ... role in normal blood cell development, helping to switch ...
... March 2011 The Nobel prize-winning physicist Richard Feynman once ... other people think?): "When I see equations, I see letters ... wonder what the hell it must look like to the ... and Feynman,s experience of "seeing" the letters in colour was ...
... Human social interactions are shaped by our ability to recognise ... the key features that enable us to identify individual people, ... and body size, that lead to a unique identity for ... has already determined the various brain regions responsible for face ...
Cached Medicine News:Health News:Researchers develop synthetic compound that may lead to drugs to fight pancreatic, lung cancer 2Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 2Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 3Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 4Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 5Health News: A Little Alcohol May Stave Off Alzheimer's 2Health News:When leukemia returns, gene that mediates response to key drug often mutated 2Health News:When leukemia returns, gene that mediates response to key drug often mutated 3Health News:Reading in 2 colours at the same time 2Health News:How do we combine faces and voices? 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: